Asure Software and Vertex have announced a strategic partnership to combine Vertex's payroll tax calculation technology with Asure's payroll tax management services. This alliance aims to offer a comprehensive end-to-end payroll tax solution to the U.S. enterprise market, expanding Asure's market share and distribution channels. The partnership will enable both companies to provide integrated payroll tax calculation, filing, remittance, and compliance services, addressing the complex and evolving payroll tax requirements across federal, state, and local jurisdictions. This collaboration positions Asure to grow beyond tax filing into a broader payroll tax technology provider, benefiting over 100,000 businesses and millions of employees nationwide.
Asure Software and Vertex announced a strategic alliance to expand payroll tax management reach. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US tech stocks, 96 rose and 40 fell. Notable movers include STM at USD 48.15 (+3.02%), AXTI at USD 56.68 (+2.93%), and CRDO at USD 155.00 (+2.66%).
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
